Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
George S. Laszlo, Brenda M. Sandmaier, Allie R. Kehret, Johnnie J. Orozco, Donald K. Hamlin, Shannon L. Dexter, Sheryl Y. T. Lim, Frances M. Cole, Jenny Huo, D. Scott Wilbur & Roland B. Walter. (2023) [211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies. Leukemia & Lymphoma 64:7, pages 1335-1339.
Read now
Read now
Articles from other publishers (14)
M. Tommy Gambles, Jiyuan Yang & Jindřich Kopeček. (2023) Multi-targeted immunotherapeutics to treat B cell malignancies. Journal of Controlled Release 358, pages 232-258.
Crossref
Crossref
Katarzyna Alicja Brzezicka & James C. Paulson. (2023) Impact of Siglecs on autoimmune diseases. Molecular Aspects of Medicine 90, pages 101140.
Crossref
Crossref
Bosen Zhuang & Ruoxi Xu. (2023) Principle and Progress of Treating Lymphoma with CD22 as Immunotherapy Target. Highlights in Science, Engineering and Technology 36, pages 577-584.
Crossref
Crossref
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, Alicia Chenoweth, David E. Thurston & Sophia N. Karagiannis. (2023) Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers 15:6, pages 1845.
Crossref
Crossref
Tahir Zaib, Ke Cheng, Tingdang Liu, Ruyi Mei, Qin Liu, Xiaoling Zhou, Lifang He, Hibba Rashid, Qingdong Xie, Hanif Khan, Yien Xu, Pingnan Sun & Jundong Wu. (2023) Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy. International Journal of Molecular Sciences 24:3, pages 2152.
Crossref
Crossref
Shankar VallabhajosulaShankar Vallabhajosula. 2023. Molecular Imaging and Targeted Therapy. Molecular Imaging and Targeted Therapy
533
575
.
Yizhen Li, Takaya MoriyamaSatoshi YoshimuraXujie ZhaoZhenhua LiXu YangElisabeth PaiettaMark R. LitzowMarina KonoplevaJiyang Yu, Hiroto Inaba, Raul C. Ribeiro, Ching-Hon Pui & Jun J. Yang. (2022) PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Science Advances 8:50.
Crossref
Crossref
Mariana Tannoury, Delphine Garnier, Santos A. Susin & Brigitte Bauvois. (2022) Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?. Cancers 14:24, pages 6026.
Crossref
Crossref
Kui-Ying Jiang, Li-Li Qi, Fu-Biao Kang & Ling Wang. (2022) The intriguing roles of Siglec family members in the tumor microenvironment. Biomarker Research 10:1.
Crossref
Crossref
Zahra Mohammadi, Somayeh Enayati, Najmeh Zarei, Mozhgan Zahmatkesh, Samaneh Saberi, Ladan Mafakher, Mohammad Azizi & Vahid Khalaj. (2022) A Novel Anti-CD22 scFv.Bim Fusion Protein Effectively Induces Apoptosis in Malignant B cells and Promotes Cytotoxicity. Applied Biochemistry and Biotechnology 194:12, pages 5878-5906.
Crossref
Crossref
Horst Prescher, Astrid Schweizer, Martin Frank, Elena Kuhfeldt, Julia Ring & Lars Nitschke. (2022)
Targeting
Human
CD22/Siglec-2 with Dimeric Sialosides as Novel Oligosaccharide Mimetics
. Journal of Medicinal Chemistry 65:15, pages 10588-10610.
Crossref
Crossref
Tingting Zhang, Tian Wang, Fengtao You, Zixuan Li, Dan Chen, Kailu Zhang, Shuaiyu Tian, Binjie Sheng, Hai Wu, Licui Jiang, Renyuxue Ma, Gangli An, Huimin Meng & Lin Yang. (2022) Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. Transplant Immunology 71, pages 101538.
Crossref
Crossref
Rita Tavarozzi & Enrica Manzato. (2022) The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use. Antibodies 11:1, pages 16.
Crossref
Crossref
Suheil Albert Atallah-Yunes & Michael J. Robertson. (2022) Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. Leukemia Research Reports 17, pages 100319.
Crossref
Crossref